Oncotarget · 2016 · 48 citations · 47 references
Life SciencesMolecular BiologyOncologyCancer PharmacologyCell SignalingSignal TransductionHeat Stress ToleranceMultiple MyelomaBortezomib TherapyCellular Heat Shock ResponseHeat Shock FactorsHeat Shock ResponseMisfolded Protein AggregationMisfolded Protein ToxicityMultiple Myeloma TherapyMultiple Myeloma Treatment
// Shardule P. Shah 1 , Ajay K. Nooka 1 , David L. Jaye 1, 2 , Nizar J. Bahlis 3 , Sagar Lonial 1 , Lawrence H. Boise 1 1 Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University and the Emory University School of Medicine, Atlanta, GA, USA 2 Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA 3 Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada Correspondence to: Lawrence H. Boise, email: lboise@emory.edu Keywords: myeloma, bortezomib, heat shock, HSF1 Received: April 26, 2016 Accepted: June 18, 2016 Published: July 26, 2016 ABSTRACT Proteasome inhibitors such as bortezomib are highly active in multiple myeloma by affecting signaling cascades and leading to a toxic buildup of misfolded proteins. Bortezomib-treated cells activate the cytoprotective heat shock response (HSR), including upregulation of heat shock proteins (HSPs). Here we inhibited the bortezomib-induced HSR by silencing its master regulator, Heat Shock Factor 1 (HSF1). HSF1 silencing led to bortezomib sensitization. In contrast, silencing of individual and combination HSPs, except HSP40β, did not result in significant bortezomib sensitization. However, HSP40β did not entirely account for increased bortezomib sensitivity upon HSF1 silencing. To determine the mechanism of HSF1 activation, we assessed phosphorylation and observed bortezomib-inducible phosphorylation in cell lines and patient samples. We determined that this bortezomib-inducible event is phosphorylation at serine 326. Prior clinical use of HSP inhibitors in combination with bortezomib has been disappointing in multiple myeloma therapy. Our results provide a rationale for targeting HSF1 activation in combination with bortezomib to enhance multiple myeloma treatment efficacy.
47
SEER Cancer Statistics Review, 1975-2003
Lynn A. G. Ries, D. Harkins, Martin Krapcho et al. · ScholarWorks - Georgia State University (Georgia State University) · 2006 · 11.5K citations · Full text
Medicine, Biostatistics, Oncology +12
Junmin Peng, Joshua E. Elias, Carson C. Thoreen et al. · Journal of Proteome Research · 2002 · 1.7K citations
Guidelines for the nomenclature of the human heat shock proteins
Harm H. Kampinga, Jurre Hageman, Michel J. Vos et al. · Cell Stress and Chaperones · 2008 · 1.4K citations · Full text
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Esther A. Obeng, Louise Carlson, Delia Gutman et al. · Blood · 2006 · 1.1K citations · Full text